ARCH Venture Partners
About ARCH Venture Partners
ARCH Venture Partners is a venture capital firm that provides seed and early-stage funding for technology-driven startups. The firm focuses on information technology, life sciences, and physical sciences, supporting disruptive science and entrepreneurship from seed to growth across multiple sectors. With a physical presence via its Chicago, Illinois address, ARCH partners with ambitious entrepreneurs to advance breakthrough companies in the United States and beyond.
Recent News
Aspen Neuroscience Lands $115M Series C
Resolve AI Raises $125M in Series A Funding at $1B Valuation
STAT+: CREATE Medicines, a Biotech Company Developing CAR-T Therapies, Raises $122 Million
The Longevity Startup That Already Has the Data Altos Labs Is Seeking: Hidden in Plain Sight
Elephas Biosciences Receives $40M Series B-2
Lifordi Immunotherapeutics Inks New Funding
Gate Bioscience Raises $65M in Series B Financing
BioSpace’s NextGen Class of 2026 Attracts Big Bucks From Tight Wallets
Paradigm Health Teams with FDA and Pharma Giants to Speed Trial Data Review
Vizgen Raises $48M in Funding
Swedish Biotech Moleculent Lands $20 Million to Advance Tissue-Level Cell Interaction Analysis
CREATE Medicines Nabs $122M Series B
Recent Deals
Moleculent Raises $20M in Funding Round Led by Rubicon Healthcare Partners
Aspen Neuroscience Secures $115M Series C Funding
Pelage Pharmaceuticals Closes $120M Series B Led by ARCH Venture Partners and GV
Kardigan Raises $254M Series B to Advance Cardiovascular Drug Development
Gate Bioscience Secures $65M Series B Round Led by Forbion and Eli Lilly
Paradigm Health Secures $78M Series B Led by ARCH Venture Partners
Elephas Biosciences Secures $40M Series B-2 Funding to Advance Live Tumor Profiling Platform
SciNeuro Pharmaceuticals Secures $53M Equity Financing
Pelage Pharmaceuticals Raises $120M in Series B Co-Led by ARCH and GV
Synchron Raises $200M in Series D Round
Lifordi Immunotherapeutics Secures Strategic Investment From Sanofi Ventures, Raising Total to $112M
CREATE Medicines Raises $122M in New Funding Round